Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

I-CURE-1: A Phase II, Single Arm Study of Pembroluzimab Combined With Carboplatin in Patients With Circulating Tumor Cells (CTCs) Positive Her-2 Negative Metastatic Breast Cancer (MBC)

NCT03213041 is registered in ClinicalTrials.gov with Northwestern University as lead sponsor.

NCT NCT03213041
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03213041 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
I-CURE-1: A Phase II, Single Arm Study of Pembroluzimab Combined With Carboplatin in Patients With Circulating Tumor Cells (CTCs) Positive Her-2 Negative Metastatic Breast Cancer (MBC)
Lead sponsor
Northwestern University
Phase
Phase 2
Overall status
Completed
Start date
September 14, 2017
Completion date
March 30, 2022
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

estrogen receptor negative, estrogen receptor positive, her2/neu negative, progesterone receptor negative, recurrent breast carcinoma, stage iv breast cancer, triple-negative breast carcinoma